Jove
Visualize
Contact Us

Related Experiment Videos

Avoiding surgery for thyroid eye disease.

P A R Meyer1

  • 1Department of Ophthalmology, Addenbrookes Hospital, Cambridge, Cambridgeshire, UK. paul.meyer@addenbrookes.nhs.uk

Eye (London, England)
|October 5, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Re-orchestration of blood flow by micro-circulations.

Eye (London, England)·2018
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Thyroid eye disease causes inflammation and swelling in the eye socket, potentially leading to vision loss. Immunomodulatory therapy effectively treats optic nerve compression and motility issues in patients with this condition.

Area of Science:

  • Ophthalmology
  • Endocrinology
  • Immunology

Background:

  • Thyroid eye disease involves autoimmune inflammation of orbital tissues, increasing orbital content and causing complications like optic nerve compression and motility disturbances.
  • Extraocular factors such as thyroid dysfunction, infections, and smoking can trigger or exacerbate orbital myopathy.

Purpose of the Study:

  • To discuss the management of thyroid eye disease (TED) by identifying and treating triggers, followed by immunomodulatory therapy.
  • To evaluate the efficacy and safety of immunomodulation in patients with TED-related compressive optic neuropathy and ocular motility disorders.

Main Methods:

  • A retrospective analysis of 14 patients with compressive optic neuropathy treated with intravenous methylprednisolone, oral prednisolone, and cyclosporin A.

Related Experiment Videos

  • Follow-up of 30 patients with severe ocular motility disturbances treated with a similar immunomodulatory regimen for a minimum of three years.

    • Main Results:

    • All patients with compressive optic neuropathy recovered pre-morbid visual acuity and visual fields.
    • Severe ocular motility disturbances resolved in the majority of treated patients.
    • Treatment-related morbidity was low, with one patient achieving ocular motility normalization with intravenous steroids and cyclosporin A alone.

    Conclusions:

    • Immunomodulatory therapy is a rational and effective approach for managing optic nerve compression and disordered motility in thyroid eye disease.
    • Identifying and treating underlying triggers of TED is crucial for successful management.
    • The described immunomodulatory regimen demonstrates a favorable safety profile and significant clinical benefits.